Share

August 2018; 8 (4) Commentary

The burnout patient

Stephen M. Sergay
First published June 18, 2018, DOI: https://doi.org/10.1212/CPJ.0000000000000482
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
817

Share

Article Information

vol. 8 no. 4 346-348
DOI: 
https://doi.org/10.1212/CPJ.0000000000000482
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received December 27, 2017
  • Accepted April 6, 2018
  • First Published June 18, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Stephen M. Sergay, MBBCh
  1. Stephen M. Sergay, MBBCh
    2. Scientific Advisory Boards:

    1. Adamas pharmaceutical company

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Tampa Neurology Associates, managing partner, neurologist, 36 years Axiom Clinical Research, Tampa, partner, neurologist, 15 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. NFL Disability Plan

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Axiom Clinical research (I am a partner). Over the last 2 years, Axiom contracted with the following companies to perform clinical research: ACCERA AVANIR PHARMACEUTICALS AXOVANT BAYER BIOGEN IDEC BIORASI / OSMOTICA CAMMS DART NEUROSCIENCE EISAI SANOFI / GENZYME ELI LILLY GENENTECH / ROCHE GLAXO SMITH KLINE HOFFMAN LaROCHE MAP PHARMACEUTICALS NOVARTIS OPEXA THERAPEUTICS PFIZER, INC RECEPTOS SANOFI-AVENTIS SUVEN TAU Rx WWCT/NEUROTOPE XENOPORT, INC

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology, School of Medicine, University of South Florida, Tampa.
  1. Correspondence
    Dr. Sergay sergay1{at}me.com
View Full Text

Article usage

Article usage: June 2018 to April 2023

AbstractFullPdfSource
Jun 20189307Highwire
Jul 201810306Highwire
Aug 201878010732Highwire
Sep 20188167316Highwire
Oct 201883261089Highwire
Nov 20182078665Highwire
Dec 20183992850Highwire
Jan 20193453022Highwire
Feb 20195935317Highwire
Mar 20192335131Highwire
Apr 20192227320Highwire
May 20191726532Highwire
Jun 20191533519Highwire
Jul 2019820316Highwire
Aug 2019433719Highwire
Sep 201951987Highwire
Oct 2019814711Highwire
Nov 201953269Highwire
Dec 2019238612Highwire
Jan 202031377Highwire
Feb 202021097Highwire
Mar 2020836519Highwire
Apr 2020325216Highwire
May 202002355Highwire
Jun 202031974Highwire
Jul 202022205Highwire
Aug 202062172Highwire
Sep 20201222112Highwire
Oct 2020132187Highwire
Nov 2020932813Highwire
Dec 202073494Highwire
Jan 2021234327Highwire
Feb 20211222110Highwire
Mar 202182405Highwire
Apr 2021326115Highwire
May 2021339318Highwire
Jun 2021623614Highwire
Jul 202142326Highwire
Aug 2021739311Highwire
Sep 2021412912Highwire
Oct 202146517Highwire
Nov 202103117Highwire
Dec 202111094Highwire
Jan 202212464Highwire
Feb 20228782Highwire
Mar 20220542Highwire
Apr 20220439Highwire
May 202223612Highwire
Jun 20220293Highwire
Jul 20220335Highwire
Aug 20221402Highwire
Sep 20222629Highwire
Oct 20223569Highwire
Nov 202287712Highwire
Dec 20224325Highwire
Jan 202346311Highwire
Feb 20238495Highwire
Mar 202317928Highwire
Apr 202310272Highwire

Cited By...

The Nerve!: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles